ASCO University serves as a comprehensive eLearning and mobile learning center that supports lifelong learning for physicians, advanced practice providers, and patient educators at every stage of their careers.

A cutting-edge health information technology platform, CancerLinQ™ enables practitioners to learn from individual patients. By assembling vast amounts of usable, searchable, real-world data, CancerLinQ seeks to improve the quality and value of cancer care.

Cancer.Net brings the expertise and resources of ASCO to people living with cancer and those who care for and about them to help patients and families make informed health care decisions.

The Conquer Cancer Foundation funds breakthrough cancer research and shares cutting-edge knowledge with patients and physicians worldwide by improving quality of and access to care and by enhancing quality of life for all who are touched by cancer.

The ASCO Institute for Quality promotes quality, value, and accountability in cancer care and further enhances the Society’s longstanding and robust efforts in the field of oncology.

Published thrice monthly, the Journal of Clinical Oncology is the foremost peer-reviewed journal focusing on clinical cancer research and the authoritative source for current information on the diagnosis and treatment of patients with cancer.

The Journal of Oncology Practice publishes peer-reviewed, original research to inform the delivery of efficient, high-quality cancer care, working to keep oncology practices current on changes and challenges inherent in delivering quality oncology care.

The Journal of Global Oncology is an online only, open access journal focused on cancer care, research, and care delivery issues unique to countries and settings with limited health care resources.

ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized clinical trial aiming to describe the performance of commercially available, targeted anticancer drugs prescribed for treatment of patients with advanced cancer with a potentially actionable genomic variant.

The ASCO Post, in partnership with the American Society of Clinical Oncology, communicates news of the highest quality multidisciplinary cancer care to a broad audience of oncology professionals and ASCO members.